|
?:abstract
|
-
BACKGROUND: An association between the severity of COVID-19 and the presence of certain chronic conditions has been suggested However, unlike influenza and other viruses, the disease burden in patients with asthma has been less evident OBJECTIVE: To understand the impact of COVID-19 in patients with asthma METHODS: Using big data analytics and artificial intelligence through the SAVANA Manager® clinical platform, we analysed clinical data from patients with asthma from January 1st to May 10th, 2020 RESULTS: Out of 71 182 patients with asthma, 1006 (1 41%) suffered from COVID-19 Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-19 were significantly older (55 versus 42 years), predominantly female (66% versus 59%), smoked more frequently, and had higher prevalence of hypertension, dyslipidemias, diabetes, and obesity Allergy-related factors such as rhinitis and eczema were less common in asthmatic patients with COVID-19 (p< 001) Higher prevalence of these comorbidities was also observed in patients with COVID-19 who required hospital admission The use of inhaled corticosteroids (ICS) was lower in patients who required hospitalisation due to COVID-19, as compared to non-hospitalised patients (48 3% versus 61 5%;OR: 0 58: 95% CI 0 44-0 77) Although patients treated with biologics (n=865;1 21%) showed increased severity and more comorbidities at the ENT level, COVID-19-related hospitalisations in these patients were relatively low (0 23%) CONCLUSION: Patients with asthma and COVID-19 were older and at increased risk due to comorbidity-related factors ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}